Acadia Pharmaceuticals (ACAD) executive compensation, 2026 proxy

Catherine Owen Adams, Chief Executive Officer, was paid $8.3M in fiscal 2025, up 9% from $7.6M the year before. The CEO-to-median-employee pay ratio was 29:1, on median employee pay of $286,045.

Filed
April 24, 2026
Annual meeting
May 29, 2026
Pay year
fiscal 2025
Named executives
5
CEO total pay
$8.3M+9% vs prior year
CEO to median employee
29:1median $286,045
CEO pay in equity
78%$6.5M in awards
Prior say-on-pay support
98%of votes cast
CEO Target Bonus
80%Percentage of base salary
NEO Target Bonus
50%Percentage of base salary for other NEOs
Annualized TSR
46%For one-year period ending Dec 31, 2025
Cash and Investments
$820.0MBalance at end of 2025

How Adams was paid

$8.3M in total for fiscal 2025, as reported in the Summary Compensation Table. Equity awards are valued at grant, not at what they turned out to be worth.

Salary11%Stock awards39%Option awards39%Non-equity incentive10%All other compensation0%

Named executive officers

ExecutiveTotal
Catherine Owen AdamsChief Executive Officer$8,256,518
Mark C. SchneyerExecutive Vice President, Chief Financial Officer$3,119,408
Jennifer J. RhodesExecutive Vice President, Chief Legal Officer and Secretary$2,927,897
Elizabeth H.Z. ThompsonExecutive Vice President, Head of Research and Development$2,888,383
Thomas GarnerExecutive Vice President, Chief Commercial Officer$3,670,951

What changed and why

  • $8.3MCatherine Owen Adams received $8,256,518 in total compensation for fiscal year 2025.
  • 89%Variable compensation represented approximately 89% of our CEO's direct compensation in 2025.
  • 110%Corporate performance portion of annual cash incentives were paid out at 110% of target.
  • 98%Approximately 98% of votes cast supported the say-on-pay proposal at the 2025 annual meeting.

About this page

Figures are automated and can be wrong; check the filing for the exact numbers. Totals follow SEC rules, which value stock and option awards at grant. Read the DEF 14A proxy statement for footnotes and the compensation committee's full reasoning.